<- Go Home
Achilles Therapeutics plc
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Market Cap
$60.8M
Volume
418.6K
Cash and Equivalents
$86.1M
EBITDA
-$67.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.51
52 Week Low
$0.63
Dividend
N/A
Price / Book Value
0.59
Price / Earnings
-0.89
Price / Tangible Book Value
0.59
Enterprise Value
-$21.6M
Enterprise Value / EBITDA
0.37
Operating Income
-$71.9M
Return on Equity
52.12%
Return on Assets
-30.17
Cash and Short Term Investments
$86.1M
Debt
$3.6M
Equity
$103.1M
Revenue
N/A
Unlevered FCF
-$44.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium